Prenatal Corticosteroids and Antioxidants in Preterm Infants

Prenatal Corticosteroids Enhance the Antioxidant Defense System in Extremely Low Gestational Age Neonates

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00791687

Acronym

RESOX

Enrollment

Registered

2008-11-14

Start date

2003-01-31

Completion date

2005-01-31

Last updated

2008-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress

Keywords

Antioxidant enzymes, Glutathione, Oxidative stress, Prematurity, Respiratory distress, Non enzymatic antioxidant defense system, Enzymatic antioxidant defense system

Brief summary

Premature infants are highly susceptible to oxidative stress because of the immaturity of their antioxidant defense system. The use of prenatal glucocorticosteroids administered to the mother improves respiratory function and overall outcome. The investigators hypothesize that prenatal glucocorticosteroids favor the expression and competence of the antioxidant defense system.

Detailed description

This is an observational study recruiting extremely low gestational age neonates (\<28 weeks gestation) whose mothers received or not full scheduled prenatal glucocorticosteroids. Healthy term newly born infants acted as controls. At birth cord blood were drawn for the following analytical determinations: reduced and oxidized glutathione; malondialdehyde; superoxide dismutase; catalase; glutathione peroxidase; glutathione reductase; glutathione s-transferase. In addition, first urine voided was collected for ortho-tyrosine/phenylalanine and 8-hydroxy-2-oxo-deoxyguanosine/2-deoxyguanosine determination. Analytical data and clinical outcomes are compared.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Gestational age \<28 weeks * Registered used or not of prenatal glucocorticosteroids by the mother

Exclusion criteria

* Use of pro-or-antioxidant drugs by the mother during gestation * Major congenital malformations * Prenatal inflammation (E.G.:chorioamnionitis) * Chromosomopathies * Uncertainty about gestational age

Design outcomes

Primary

Measure	Time frame
Evaluation of glutathione redox status in cord blood.	at birth

Secondary

Measure	Time frame
Evaluation of antioxidant activity.	at birth

Countries

Spain

Outcome results